Sweta Dalal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sweta Dalal has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Pooja Dalal
Department of Pharmaceutical sciences, Guru Jambheshwar University of science and Technology, Hisar 125001, India
3 shared publications - Rekha Rao
Department of Pharmaceutical sciences, Guru Jambheshwar University of science and Technology, Hisar 125001, India
3 shared publications - Sunil Kumar
Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
3 shared publications - Anroop Balachandran Nair
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
2 shared publications - Varsha Kadian
Department of Pharmaceutical sciences, Guru Jambheshwar University of science and Technology, Hisar 125001, India
2 shared publications - Babu Lal Jangir
Department of Veterinary Pathology, College of Veterinary Science, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar-125004, Haryana, India
1 shared publication
Latest Publications
- 13 November 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 1-19
Novel Capsaicin Nanogel for Arthritic Pain and Inflammation Management: Formulation, In Vitro, Ex-vivo and In Vivo Assessment
The present work aimed to prepare and evaluate novel capsaicin (CAP) loaded nanosponges (NS) embedded Carbopol hydrogel (CAPNS-HG) with rosemary oil (RO) f
- 13 November 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 1-19
Novel Capsaicin Nanogel for Arthritic Pain and Inflammation Management: Formulation, In Vitro, Ex-vivo and In Vivo Assessment
The present work aimed to prepare and evaluate novel capsaicin (CAP) loaded nanosponges (NS) embedded Carbopol hydrogel (CAPNS-HG) with rosemary oil (RO) f
- Open Access
- 11 March 2022
- Published by MDPI AG in Future Pharmacology
- Vol. 2 (1) , 64-91
A Fresh Look on Bergenin: Vision of Its Novel Drug Delivery Systems and Pharmacological Activities
Bergenin (BER), a key constituent of Bergenia crassifolia (Saxifragaceae), has gained extensive attention, owing to its array of pharmacological actions, including anti-infective, anti-cancer, anti-diabetic, neuroprotective, hepatoprotective, anti-urolithiatic, anti-hyperuricemic, and anti-bradykinin properties. Despite ever-intensifying support for its therapeutic features, the poor solubility, lower oral bioavailability, shorter half-life, and more intestinal pH degradation (pH 6.8 or above) of BER have puzzled researchers. To circumvent these pharmaceutical challenges, and to improve its therapeutic efficacy, newer approaches have been adopted by research scientists. Thus, a discussion of the existing literature may provide complete information about the advances in delivery strategies for enhancing its utility. This paper summarizes up-to-date works on the design and development of novel delivery carriers of this bioactive compound, such as phospholipid complexes, extended-release core tablets, prodrugs, herbal gels, polyherbal ointments, nanoparticles, and poly (lactic acid) polymers, with the objective of harnessing its full potential. This review also provides a deep insight into its bioactivities, along with mechanisms. Additionally, the physicochemical attributes, chemistry, and pharmacokinetics of BER are discussed herein. Hence, the comprehensive information documented in this review may introduce new avenues for research advancements of BER.
- 11 March 2022
- Published by MDPI AG in Future Pharmacology
- Vol. 2 (1) , 64-91
Open AccessA Fresh Look on Bergenin: Vision of Its Novel Drug Delivery Systems and Pharmacological Activities
Bergenin (BER), a key constituent of Bergenia crassifolia (Saxifragaceae), has gained extensive attention, owing to its array of pharmacological actions, including anti-infective, anti-cancer, anti-diabetic, neuroprotective, hepatoprotective, anti-urolithiatic, anti-hyperuricemic, and anti-bradykinin properties. Despite ever-intensifying support for its therapeutic features, the poor solubility, lower oral bioavailability, shorter half-life, and more intestinal pH degradation (pH 6.8 or above) of BER have puzzled researchers. To circumvent these pharmaceutical challenges, and to improve its therapeutic efficacy, newer approaches have been adopted by research scientists. Thus, a discussion of the existing literature may provide complete information about the advances in delivery strategies for enhancing its utility. This paper summarizes up-to-date works on the design and development of novel delivery carriers of this bioactive compound, such as phospholipid complexes, extended-release core tablets, prodrugs, herbal gels, polyherbal ointments, nanoparticles, and poly (lactic acid) polymers, with the objective of harnessing its full potential. This review also provides a deep insight into its bioactivities, along with mechanisms. Additionally, the physicochemical attributes, chemistry, and pharmacokinetics of BER are discussed herein. Hence, the comprehensive information documented in this review may introduce new avenues for research advancements of BER.
- Open Access
- 9 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 383
Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.
- 9 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 383
Open AccessNovel Dermal Delivery Cargos of Clobetasol Propionate: An Update
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.